Moores Launches AI and Precision Oncology Fellowship with Illumina Support
|
Inaugural Fellow Aaron Boussina, PhD (Assistant Professor, UC San Diego, School of Medicine, Department of Medicine) is applying AI and genomics tools for the early detection of cancers such as pancreatic cancer. Learn More»
|
|
|
Moores Member Co-Authors New Bioinformatics Tool
|
Congratulations to Jill Mesirov, PhD, whose latest efforts in bioinformatics has generated igv-reports, a Python tool that generates self-contained HTML pages with interactive genomic visualizations to streamline variant review workflows. Learn More»
|
|
|
Moores Members Champion Individualized Cancer Treatment
|
Congratulations to Jason Sicklick, MD and Shumei Kato, MD, whose I-PREDICT trial demonstrates that tailoring multi-drug regimens to a given patient's unique tumor profile improves survival outcomes, with fewer severe side effects than standard care. Read Medical Xpress Feature» | Read JMIR Feature»
|
|
|
Moores Director Highlights Pancreatic Cancer Risk and Early Detection
|
Diane Simeone, MD spoke with HealthyWomen on pancreatic cancer risk factors, germline testing, and the importance of seeking care at a specialized center of expertise. Learn More»
|
|
|
Moores Member Featured on OncLive for Prostate Cancer Trial
|
Congratulations to Rana McKay, MD, whose findings from the Phase IV OPTYX trial, which evaluates relugolix in advanced prostate cancer, were featured on OncLive, following her presentation at the 2026 Genitourinary Cancers Symposium. Learn More»
|
|
|
Next Monday, April 27, 2026 from 4:00 p.m. to 5:00 p.m., Moores Director Diane Simeone, MD will lead this update on progress being made at Moores. RSVP Now»
|
|
|
|
MOORES CANCER CENTER AT AACR |
The 2026 AACR Annual Meeting will take place April 17–22 in San Diego, where Moores Members will present their research on immunology, computational biology, and early detection and prevention through over 30 sessions.
|
|
|
|
FEATURED FUNDING OPPORTUNITIES |
|
|
|
Point of Care Technology Research Network (POCTRN)
|
Innovation Award Opportunity to Support the Development of Point-of-Care Technologies in Nutrition, Infection, and Cancer
Application Deadline: May 1, 2026
Award: $50,000–$100,000 for 12 months
|
|
|
Point-of-Care Tools to Improve Detection of Pre-Cancer and Early Cancer in Hospital, Mobile, Community, and Home Settings
Application Deadline: May 1, 2026
Award: $75,000–$150,000 for 6–12 months
|
|
|
The Atlanta Center for Microsystems Engineered Point-of-Care Technologies
Application Deadline: May 1, 2026
Award: $50,000–$250,000 for 1 year
|
|
|
RECENT MEMBER PUBLICATIONS |
|
|
|
|
Enhancing capacity in faith-based organizations to implement and sustain multilevel innovations to improve physical activity: Study protocol for the faith in action type II hybrid implementation-effectiveness trial
|
BMC Public Health
Elva Arredondo, PhD (Cancer Control), Borsika Rabin, PhD, MPH, PharmD (Cancer Control), and Guadalupe Ayala, PhD (Cancer Control)
|
|
|
|
Colorectal cancer and mortality risk among older adults with vs without adenoma on prior colonoscopy
|
JAMA
Samir Gupta, MD (Cancer Control), Joshua Demb, PhD (Cancer Control), and Shailja Shah, MD, MPH (Cancer Control)
|
|
|
| Functional neuroimaging biomarkers of impaired neurocognition after proton beam radiotherapy for brain tumors in pediatric patients: A prospective trial
|
Neuro-oncology
Kathryn Tringale, MD (Hematologic Malignancies), Jona Hattangadi-Gluth, MD (Solid Tumor Therapeutics), and Carrie McDonald, PhD (N/A)
|
|
|
c24-349: A Randomized Open-label Phase II Study of TALazoparib with or without ENzaluTamide in Patients with Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate
PI: Rana McKay, MD
NCT ID: NCT06844383
GO46021: A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor
PI: Kay T. Yeung, MD, PhD
NCT ID: NCT07100106
UCSD 813314: StratEgic hormoNe therapy and Targeted RadiotherapY (SENTRY)
PI: Tyler Seibert, MD, PhD
NCT ID: NCT07364071
|
|
|
|
|
